BOSTON and LAUSANNE, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq:...
SOPHiA GENETICS to Participate in Fireside Chat at 20th Annual Morgan Stanley Global Healthcare Conference
read more
Summer 2022 Newsletter
Attend/Stream...
The Launch of SOPHiA DDM™ Dispatch
SOPHiA GENETICS is excited to announce the launch of SOPHiA DDM™ Dispatch, a new way for our SOPHiA GENETICS Integrated Access partner labs to work with their clients. SOPHiA DDM™ Dispatch make its it easier to work with clients directly and control logistics within your lab.
Considerations for whole exome sequencing
Whole exome sequencing can present a goldilocks option between targeted gene panels and whole genome sequencing. Dive into some of the considerations for adopting whole exome sequencing in your institution.
SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2022
Steady Operational Performance Amidst Macroeconomic Headwinds BOSTON and LAUSANNE, Switzerland,...
SOPHiA GENETICS to Host Investor Day on September 20, 2022, in New York City
BOSTON and LAUSANNE, Switzerland, Aug. 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq:...
Partner Spotlight: Dr Alessandra Terracciano
Read about our successful collaborations, Dr Terracciano’s favorite SOPHiA DDM™ Platform features, and what she sees in the future for SOPHiA GENETICS.
SOPHiA GENETICS to Participate in Canaccord Genuity 42nd Annual Growth Conference
BOSTON and LAUSANNE, Switzerland, July 29, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq:...
The Andalusian Health Service conduct trio analysis with the SOPHiA DDM™ Platform to identify the underlying cause of 2 neonatal deaths
The SOPHiA DDM Platform was a very useful tool for resolving this complex case.
SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2022 on August 9, 2022
BOSTON and LAUSANNE, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq:...
Application Note: The SOPHiA DDM™️ Platform for Neurological Disorders
Check out our step-by-step guide to using SOPHiA DDM™️ complemented by Alamut™️ Visual Plus to streamline the interpretation of clinical exome data for neurological disorders.
Seven reasons to choose SOPHiA DDM™ Dx RNAtarget Oncology Solution for gene fusion detection
Cancer management outcomes can strongly benefit from robust and accurate detection of gene fusions. SOPHiA GENETICS developed the SOPHiA DDM™ Dx RNAtarget Oncology Solution to make this possible.
We list 7 reasons to consider SOPHiA DDM™ Dx RNAtarget Oncology Solution for your assays.